The new chief executive of Roche has embraced a broadening of the Swiss pharmaceutical group’s focus from hospital-based medicines to primary care treatments, provided they offer significantly greater benefits than existing drugs.
The new chief executive of Roche has embraced a broadening of the Swiss pharmaceutical group’s focus from hospital-based medicines to primary care treatments, provided they offer significantly greater benefits than existing drugs.